Recently, Dejin Biotech announced the completion of a Series A financing round worth tens of millions of RMB. The round was led by a prominent biopharmaceutical investment firm, with participation from several existing shareholders. The proceeds will be primarily used to advance preclinical and early-stage clinical development of its core pipeline, optimize its proprietary technology platform, and expand its R&D team. Dejin Biotech is an innovative biotechnology company focused on gene editing and cell therapy, dedicated to developing next-generation treatments for rare and serious diseases. Leveraging its self-developed high-precision gene editing platform, the company has significantly enhanced editing efficiency while minimizing off-target effects, establishing a robust pipeline of globally competitive drug candidates. This successful financing round underscores strong investor confidence in Dejin’s technological capabilities and strategic vision, providing critical support for accelerating its pipeline and expanding its global footprint. Moving forward, Dejin Biotech will continue to pioneer advancements in gene and cell therapy, translating innovative therapies from the lab to the clinic to benefit patients worldwide.
近日，德进生物宣布完成数千万元人民币的A轮融资，本轮融资由知名生物医药投资机构领投，多家老股东跟投。资金将主要用于推进其核心管线的临床前及早期临床研究、技术平台优化以及团队建设。德进生物是一家专注于基因编辑与细胞治疗领域的创新生物技术公司，致力于开发针对罕见病和重大疾病的下一代疗法。公司依托自主研发的高精度基因编辑平台，在提高编辑效率的同时显著降低脱靶风险，已建立起多个具有全球竞争力的候选药物项目。此次融资的成功，不仅体现了资本市场对德进生物技术实力和研发策略的高度认可，也为其加速产品管线推进和国际化布局提供了坚实支撑。未来，德进生物将持续深耕基因与细胞治疗领域，推动更多创新疗法从实验室走向临床，惠及全球患者。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/18760.html